Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: The OITA-GF study

QJM: An International Journal of Medicine

Volumn 104, Issue 2, 2011, Pages 133-139

  Tamura, A ^a   Murakami, K ^a   Kadota, J ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZULENE DERIVATIVE; CALCIUM ANTAGONIST; CETRAXATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECEBET; FAMOTIDINE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NITRATE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLAUNOTOL; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; REBAMIPIDE; SOFALCONE; TEPRENONE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL MUCOSA; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH EROSION; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 78751682908     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq169     Document Type: Article

References (19)

1. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease, stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science advisory and coordinating committee. Circulation 2002; 106:388-91.
2. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115:1481-501.
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med 2002; 136:161-72.
4. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction). J Am Coll Cardiol 2008; 51:210-47.
5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons, endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1-e157.
6. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310:827-30.
7. Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95:2218-24.
8. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22:795-801.
9. Nema H, Kato M, Katsurada T, Nozaki Y, Yotsukura A, Yoshida I, et al. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease. J Clin Gastroenterol 2009; 43:130-2.
10. Niv Y, Battler A, Abuksis G, Gal E, Sapoznikov B, Vilkin A. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005; 50:78-80.
11. Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ. Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? Gastroenterology 2002; 123:1451-8.
12. Katsuragi K, Noda A, Tachikawa T, Azuma A, Mukai F, Murakami K, et al. Highly sensitive urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori. Helicobacter 1998; 3:289-95.
13. Kato M, Asaka M, Saito M, Sekine H, Ohara S, Toyota T, et al. Clinical usefulness of urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori: a collaborative study in nine medical institutions in Japan. Helicobacter 2000; 5:109-19.
14. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32:77-83.
15. Hawkey CJ. Review article: aspirin and gastrointestinal bleeding. Aliment Pharmacol Ther 1994; 8:141-6.
16. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033-8.
17. Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007; 102:2411-6.
18. Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103:2465-73.
19. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:119-25.